



**Australian Government**  
**Department of Health and Ageing**  
**Therapeutic Goods Administration**

**THERAPEUTIC GOODS ACT 1989**

I, MICHAEL DODSON, Director, Non-Prescription Medicines Branch, Therapeutic Goods Administration and delegate of the Secretary to the Department of Health and Ageing for the purposes of section 42 DK (1) of the Therapeutic Goods Act, give notice that the restricted representations described in paragraph (a) below, being representations that are necessary for the appropriate use of the therapeutic goods described in paragraph (b) below, may be included either on the label of the package of those goods or in information included in the package in which those goods are contained:

- (a) representations to the effect that the goods described in paragraph (b) below may be used **“For the treatment of patients with known cardiovascular or cerebrovascular disease, as an antiplatelet agent for prophylaxis against acute myocardial infarction, unstable angina, transient ischaemic attack and cerebrovascular accident (stroke)”** and **“Reduces the risk of heart attack and stroke in patients with known cardiovascular or cerebrovascular disease”**.

- (b) **CHEMMART PHARMACY EC ASPIRIN 100 aspirin 100mg tablet blister pack**

supplied as an over-the-counter drug by Symbion Pharmacy Services Pty Ltd.

Dated this 12<sup>th</sup> day of June 2010.

A handwritten signature in dark ink, appearing to read 'MD', followed by a horizontal line.

MICHAEL DODSON  
Delegate of the Secretary to the Department of  
Health and Ageing